Singapore, 9th January 2025
Location: SGX Auditorium, 2 Shenton Way, SGX Centre 1, Level 2, Singapore
Gene Solutions (GS), a pioneer genomic testing company in South-East Asia, and August Global Partners (AGP), a global healthcare investor, are pleased to announce the signing of a Memorandum of Understanding (MoU). GS will support broader adoption of precision medicine and targeted therapeutics in Asia through the development of a suite of AI technologies that encompass a scientific knowledge base, large language models (LLM), multi-omics insights, and clinical database to push the boundaries of next-generation sequencing (NGS) services.
The AI suite, named DNAsphere.AI, was developed by GS through years of clinical research partnerships and DNA testing expertise across both reproductive health and oncology verticals. With this AI suite, GS can reduce sequencing costs while significantly improving test performance, consequently increasing the accessibility of personalized solutions.
AGP is investing in GS through a proprietary funding round and will assist them in enhancing the performance of their oncology solutions by providing access to world-class research resources and regional partners. This will enable GS to further validate its test accuracy and implement the DNAsphere.AI suite in personalized cancer treatment applications.
GS is now expanding its product portfolio in personalized cancer care to the global market. This includes their renowned early cancer detection (“SPOT-MAS”)1 and cancer monitoring tests (“K-TRACK”)2. More recently, the company announced the launch of single-cancer early detection (SCED) tests developed with AI-driven ctDNA technology, aimed at improving early cancer screening adherence in asymptomatic populations. GS also has ongoing programs with biopharma leaders to co-develop novel cancer therapeutics, such as targeted cancer drugs, neoantigen vaccines, and cell therapies.
Quotes from Leadership:
- Dr. Nguyen Hoai Nghia, CEO & Chairman, GS: “Cancer is a debilitating disease that has impacted many of our loved ones or ourselves profoundly. This partnership is a pivotal milestone in our company’s mission to provide advanced and accessible oncology solutions. By combining our genomic expertise with AGP’s investment and network, we aim to make blood-based cancer screening and treatment monitoring tests more accurate and more affordable.”
- Dr. Basil Lui, Founding Partner, AGP: “Genomic technologies can revolutionize cancer management via earlier detection and personalized treatment insights, and GS is an emerging leader in providing affordable high-quality tests. As more tests are delivered and validated, GS can further build competitive advantage from the AI flywheel effect. Our investment underscores our commitment to visionary entrepreneurs and innovation-led healthcare solutions.”
About Gene Solutions:
A pioneer biotech company in Asia, known for its innovative reproductive and oncology solutions. GS has provided over 2,000,000 cell-free DNA tests in the region, including more than 60,000 tumor profiling tests and over 20,000 multi-cancer early detection tests. With two College of American Pathologists (“CAP”) accredited laboratories in Singapore and Ho Chi Minh City, GS is at the forefront of providing accessible and critical insights to improve reproductive health and cancer care in the region.
About August Global Partners:
A growth-oriented, global investment firm from Singapore investing in the theme of “Living Better, Aging Better.” With an extensive network cultivated through decades of global investment experience in areas such as healthcare-related technologies and bio-innovations, and backed by a diverse array of financial investors, conglomerates, and institutions, AGP provides value-added capital to the next generation of founders and innovators who are shaping the future of healthcare in Asia and the world.
1 SPOT-MAS is a non-invasive, multi-cancer early detection (MCED) test that detects circulating tumor DNA (ctDNA) in the blood from 10 types of cancers (breast, lung, colorectum, stomach, liver-biliary tract, ovary, pancreas, esophagus, uterus, head & neck).
2 K-TRACK is a longitudinal circulating tumor DNA (ctDNA) monitoring tests that facilitates early detection of cancer recurrence and evaluation of treatment effectiveness.
